Top Story

UNITY-2: Patients with HCV, cirrhosis achieve SVR12 on fixed-dose regimen

UNITY-2: Patients with HCV, cirrhosis achieve SVR12 on fixed-dose regimen
May 5, 2015

Treatment-naive and experienced patients with chronic hepatitis C virus genotype 1 infection and cirrhosis achieved a sustained virologic response at 12 weeks while on a fixed-dose regimen of daclatasvir, asunaprevir and beclabuvir, according to newly published data in JAMA.

In the UNITY-2 trial, researchers, including Andrew J. Muir, MD, of the Duke Clinical Research Institute at the Duke University School of Medicine in North Carolina, randomly assigned 112 treatment-naive patients and 90 treatment-experienced patients to receive a twice daily, fixed-dose combination of 30 mg of daclatasvir (Bristol-Myers Squibb), 200 mg of asunaprevir (Bristol-Myers Squibb) and 75 mg of beclabuvir (BMS-791325, Bristol-Myers Squibb) with or without ribavirin for 12 weeks.

Meeting News Coverage

Vancomycin powder may help protect against spinal surgical site infections

May 5, 2015
WASHINGTON, D.C. — The use of intrawound vancomycin powder can assist in the prevention of surgical site infections in spine surgery; however, the indiscriminate…
In the Journals

UNITY-1: Fixed-dose combo yields high SVR12 in HCV patients without cirrhosis

May 5, 2015
Treatment-naive and experienced patients with chronic hepatitis C virus genotype 1 infection without cirrhosis achieved a sustained virologic response at 12 weeks while…
In the Journals

PX-UV light reduces aerobic bacteria in hospital rooms

May 5, 2015
Pulsed xenon ultraviolet light systems effectively disinfected aerobic bacteria in the absence of manual disinfection, according to research published in the American
Meeting News Coverage

Oral DAAs effective for HIV/HCV patients

May 5, 2015
New all-oral, direct-acting antiviral agents were well tolerated and showed encouraging signs of virological efficacy in a study of cirrhotic patients coinfected with…
More News Headlines »
CME
j526

Regimen Selection in HIV: Considering New Options to Optimize Outcomes

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than two decades into the antiretroviral therapy (ART) era, there are numerous options for HIV treatment. The goal…
More »
Meeting News Coverage Video
VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

April 24, 2015
BETHESDA, Md. — Richard K. Zimmerman, MD, of the University of Pittsburgh, explains the results of his study…
More »
CME
Conjuctivitis

Management of Pediatric Conjunctivitis and Otitis/Conjunctivitis Syndrome

This activity is supported by an educational grant from Alcon Research, LTD.

Acute bacterial conjunctivitis affects approximately 1 of every 8 children each year, and 5 million cases occur in the…
More »